Autoimmunity in 2011

Clinical Reviews in Allergy and Immunology

Volumn 43, Issue 1-2, 2012, Pages 194-206

  Selmi, Carlo ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Environmental factors; Genetics; IL17; Tolerance breakdown

Indexed keywords

MONOCLONAL ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CLINICAL RESEARCH; ENVIRONMENTAL FACTOR; GENETIC ASSOCIATION; GENOMICS; HEREDITY; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYOSITIS; NONHUMAN; PATHOGENESIS; PRIMARY BILIARY CIRRHOSIS; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; SCLERODERMA; SCREENING; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TH17 CELL;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; ENVIRONMENT; EPIGENESIS, GENETIC; HUMANS; IMMUNE TOLERANCE;

EID: 84871669272     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-012-8330-2     Document Type: Article

References (219)

1. Selmi C (2011) Autoimmunity in 2010. Autoimmun Rev 10:725-732
2. Arnaud L, Zahr N, Costedoat-Chalumeau N, Amoura Z (2011) The importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosus. Autoimmun Rev 10:674-678
3. Balsamo S, Santos-Neto LD (2011) Fatigue in systemic lupus erythematosus: an association with reduced physical fitness. Autoimmun Rev 10:514-518
4. Campar A, Farinha F, Vasconcelos C (2011) Refractory disease in systemic lupus erythematosus. Autoimmun Rev 10:685-692
5. Dong W, Zhu P, Wang Y, Wang Z (2011) Follicular helper T cells in systemic lupus erythematosus: a potential therapeutic target. Autoimmun Rev 10:299-304
6. Hsieh CC, Lin BF (2011) Dietary factors regulate cytokines in murine models of systemic lupus erythematosus. Autoimmun Rev 11:22-27
7. Leng RX, Pan HF, Chen GM, Feng CC, Fan YG, Ye DQ et al (2011) The dual nature of Ets-1: focus to the pathogenesis of systemic lupus erythematosus. Autoimmun Rev 10:439-443
8. Murdaca G, Colombo BM, Puppo F (2011) Emerging biological drugs: a new therapeutic approach for systemic lupus erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 11:56-60
9. Newman KA, Akhtari M (2011) Management of autoimmune neutropenia in Felty's syndrome and systemic lupus erythematosus. Autoimmun Rev 10:432-437
10. Sawla P, Hossain A, Hahn BH, Singh RP (2012) Regulatory T cells in systemic lupus erythematosus (SLE); role of peptide tolerance. Autoimmun Rev 11:611-614
11. Atisha-Fregoso Y, Jakez-Ocampo J, Llorente L (2011) Systemic lupus erythematosus in Hispanics. Autoimmunity 44:555-561
12. Minowa K, Amano H, Nakano S, Ando S, Watanabe T, Nakiri Y et al (2011) Elevated serum level of circulating syndecan-1 (CD138) in active systemic lupus erythematosus. Autoimmunity 44:357-362
13. Wen F, Ellingson SM, Kyogoku C, Peterson EJ, Gaffney PM (2011) Exon 6 variants carried on systemic lupus erythematosus (SLE) risk haplotypes modulate IRF5 function. Autoimmunity 44:82-89
14. Fu SM, Deshmukh US, Gaskin F (2011) Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 37:104-112
15. Ullal AJ, Reich CF 3rd, Clowse M, Criscione-Schreiber LG, Tochacek M, Monestier M et al (2011) Microparticles as antigenic targets of antibodies to DNA and nucleosomes in systemic lupus erythematosus. J Autoimmun 36:173-180
16. Zhang Q, Long H, Liao J, Zhao M, Liang G, Wu X et al (2011) Inhibited expression of hematopoietic progenitor kinase 1 associated with loss of jumonji domain containing 3 promoter binding contributes to autoimmunity in systemic lupus erythematosus. J Autoimmun 37:180-189
17. Bethunaickan R, Berthier CC, Ramanujam M, Sahu R, Zhang W, Sun Y et al (2011) A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 186:4994-5003
18. Horton HM, Chu SY, Ortiz EC, Pong E, Cemerski S, Leung IW et al (2011) Antibody-mediated coengagement of FcgammaRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus. J Immunol 186:4223-4233
19. Huang W, Moisini I, Bethunaickan R, Sahu R, Akerman M, Eilat D et al (2011) BAFF/APRIL inhibition decreases selection of naive but not antigen-induced autoreactive B cells in murine systemic lupus erythematosus. J Immunol 187:6571-6580
20. Lichtnekert J, Rupanagudi KV, Kulkarni OP, Darisipudi MN, Allam R, Anders HJ (2011) Activated protein C attenuates systemic lupus erythematosus and lupus nephritis in MRL-Fas(lpr) mice. J Immunol 187:3413-3421
21. Liu Z, Bethunaickan R, Huang W, Ramanujam M, Madaio MP, Davidson A (2011) IFN-alpha confers resistance of systemic lupus erythematosus nephritis to therapy in NZB/WF1 mice. J Immunol 187:1506-1513
22. McPhee CG, Sproule TJ, Shin DM, Bubier JA, Schott WH, Steinbuck MP et al (2011) MHC class I family proteins retard systemic lupus erythematosus autoimmunity and B cell lymphomagenesis. J Immunol 187:4695-4704
23. Alessandri C, Conti F, Pendolino M, Mancini R, Valesini G (2011) New autoantigens in the antiphospholipid syndrome. Autoimmun Rev 10:609-616
24. Blank M, Baraam L, Eisenstein M, Fridkin M, Dardik R, Heldman Y et al (2011) beta2-Glycoprotein-I based peptide regulate endothelial-cells tissue-factor expression via negative regulation of pGSK3beta expression and reduces experimental-antiphospholipid-syndrome. J Autoimmun 37:8-17
25. Ceccarelli F, Chighizola C, Finazzi G, Meroni PL, Valesini G (2012) Thromboprophylaxis in carriers of antiphospholipid antibodies (APL) without previous thrombosis: "pros" and "cons". Autoimmun Rev 11:568-571
26. Cervera R, Conti F, Doria A, Iaccarino L, Valesini G (2012) Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev 11:581-584
27. Espinosa G, Berman H, Cervera R (2011) Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 10:664-668
28. Font C, Vidal L, Espinosa G, Tassies D, Monteagudo J, Farrus B et al (2011) Solid cancer, antiphospholipid antibodies, and venous thromboembolism. Autoimmun Rev 10:222-227
29. Martin E, Winn R, Nugent K (2011) Catastrophic antiphospholipid syndrome in a community-acquired methicillin-resistant Staphylococcus aureus infection: a review of pathogenesis with a case for molecular mimicry. Autoimmun Rev 10:181-188
30. Medina G, Gutierrez-Moreno AL, Vera-Lastra O, Saavedra MA, Jara LJ (2011) Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients. Autoimmun Rev 10:214-217
31. Mirarabshahi P, Abdelatti M, Krilis S (2011) Post-translational oxidative modification of beta2-glycoprotein I and its role in the pathophysiology of the antiphospholipid syndrome. Autoimmun Rev. doi:10.1016/j.autrev.2011.12.007
32. Pengo V, Ruiz-Irastorza G, Denas G, Andreoli L, Khamashta M, Tincani A (2012) High intensity anticoagulation in the prevention of the recurrence of arterial thrombosis in antiphospholipid syndrome: 'PROS' and 'CONS'. Autoimmun Rev 11:577-580
33. Pittschieler S, Wiedermann FJ (2011) Catastrophic antiphospholipid syndrome associated with methicillin-resistant Staphylococcus aureus infection. Autoimmun Rev 10:238
34. Saponjski J, Stojanovich L, Djokovic A, Petkovic M, Mrda D (2011) Systemic vascular diseases in the antiphospholipid syndrome. What is the best diagnostic choice? Autoimmun Rev 10:235-237
35. Irman S, Skarabot M, Musevic I, Rozman B, Bozic B (2011) The use of atomic force microscopy to study the pathologic effects of anti-annexin autoantibodies. J Autoimmun 36:98-105
36. Almeida I, Faria R, Vita P, Vasconcelos C (2011) Systemic sclerosis refractory disease: from the skin to the heart. Autoimmun Rev 10:693-701
37. Arnson Y, Amital H, Agmon-Levin N, Alon D, Sanchez-Castanon M, Lopez-Hoyos M et al (2011) Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 10:490-494
38. Bosello S, De Luca G, Tolusso B, Lama G, Angelucci C, Sica G et al (2011) B cells in systemic sclerosis: a possible target for therapy. Autoimmun Rev 10:624-630
39. Bussone G, Mouthon L (2011) Interstitial lung disease in systemic sclerosis. Autoimmun Rev 10:248-255
40. Chighizola C, Shoenfeld Y, Meroni PL (2011) Systemic sclerosis. Introduction. Autoimmun Rev 10:239-240
41. Chizzolini C, Brembilla NC, Montanari E, Truchetet ME (2011) Fibrosis and immune dysregulation in systemic sclerosis. Autoimmun Rev 10:276-281
42. Cipriani P, Marrelli A, Liakouli V, Di Benedetto P, Giacomelli R (2011) Cellular players in angiogenesis during the course of systemic sclerosis. Autoimmun Rev 10:641-646
43. Dieude P, Boileau C, Allanore Y (2011) Immunogenetics of systemic sclerosis. Autoimmun Rev 10:282-290
44. Galluccio F, Matucci-Cerinic M (2011) Two faces of the same coin: Raynaud phenomenon and digital ulcers in systemic sclerosis. Autoimmun Rev 10:241-243
45. Godard D (2011) The needs of patients with systemic sclerosis - what are the difficulties encountered? Autoimmun Rev 10:291-294
46. Grossman C, Dovrish Z, Shoenfeld Y, Amital H (2011) Do infections facilitate the emergence of systemic sclerosis? Autoimmun Rev 10:244-247
47. Liakouli V, Cipriani P, Marrelli A, Alvaro S, Ruscitti P, Giacomelli R (2011) Angiogenic cytokines and growth factors in systemic sclerosis. Autoimmun Rev 10:590-594
48. Nielsen LB, Vaziri-Sani F, Porksen S, Andersen ML, Svensson J, Bergholdt R et al (2011) Relationship between ZnT8Ab, the SLC30A8 gene and disease progression in children with newly diagnosed type 1 diabetes. Autoimmunity 44:616-623
49. Nussinovitch U, Shoenfeld Y (2011) Atherosclerosis and macrovascular involvement in systemic sclerosis: myth or reality. Autoimmun Rev 10:259-266
50. Tiev KP, Cabane J (2011) Digestive tract involvement in systemic sclerosis. Autoimmun Rev 11:68-73
51. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J (2011) Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev 10:267-275
52. Besliu A, Banica L, Predeteanu D, Vlad V, Ionescu R, Pistol G et al (2011) Peripheral blood lymphocytes analysis detects CD100/SEMA4D alteration in systemic sclerosis patients. Autoimmunity 44:427-436
53. Rodriguez-Reyna TS, Hinojosa-Azaola A, Martinez-Reyes C, Nunez-Alvarez CA, Torrico-Lavayen R, Garcia-Hernandez JL et al (2011) Distinctive autoantibody profile in Mexican Mestizo systemic sclerosis patients. Autoimmunity 44:576-584
54. Takagi K, Kawaguchi Y, Kawamoto M, Ota Y, Tochimoto A, Gono T et al (2011) Activation of the activin A-ALK-Smad pathway in systemic sclerosis. J Autoimmun 36:181-188
55. Atzeni F, Sarzi-Puttini P, Gorla R, Marchesoni A, Caporali R (2011) Switching rheumatoid arthritis treatments: an update. Autoimmun Rev 10:397-403
56. Ballanti E, Perricone C, di Muzio G, Kroegler B, Chimenti MS, Graceffa D et al (2011) Role of the complement system in rheumatoid arthritis and psoriatic arthritis: relationship with anti-TNF inhibitors. Autoimmun Rev 10:617-623
57. Chao CC, Chen SJ, Adamopoulos IE, Davis N, Hong K, Vu A et al (2011) Anti-IL-17A therapy protects against bone erosion in experimental models of rheumatoid arthritis. Autoimmunity 44:243-252
58. Chatzikyriakidou A, Voulgari PV, Georgiou I, Drosos AA (2012) miRNAs and related polymorphisms in rheumatoid arthritis susceptibility. Autoimmun Rev 11:636-641
59. Chimenti MS, Graceffa D, Perricone R (2011) Anti-TNFalpha discontinuation in rheumatoid and psoriatic arthritis: is it possible after disease remission? Autoimmun Rev 10:636-640
60. Costenbader KH, Prescott J, Zee RY, De Vivo I (2011) Immunosenescence and rheumatoid arthritis: does telomere shortening predict impending disease? Autoimmun Rev 10:569-573
61. Dominguez Mdel C, Lorenzo N, Barbera A, Darrasse-Jeze G, Hernandez MV, Torres A et al (2011) An altered peptide ligand corresponding to a novel epitope from heat-shock protein 60 induces regulatory T cells and suppresses pathogenic response in an animal model of adjuvant-induced arthritis. Autoimmunity 44:471-482
62. Gremese E, Ferraccioli G (2011) The metabolic syndrome: the crossroads between rheumatoid arthritis and cardiovascular risk. Autoimmun Rev 10:582-589
63. Hickman-Brecks CL, Racz JL, Meyer DM, LaBranche TP, Allen PM (2011) Th17 cells can provide B cell help in autoantibody induced arthritis. J Autoimmun 36:65-75
64. Iobagiu C, Magyar A, Nogueira L, Cornillet M, Sebbag M, Arnaud J et al (2011) The antigen specificity of the rheumatoid arthritis-associated ACPA directed to citrullinated fibrin is very closely restricted. J Autoimmun 37:263-272
65. Kurz K, Herold M, Winkler C, Klotz W, Russe E, Fuchs D (2011) Effects of adalimumab therapy on disease activity and interferongamma-mediated biochemical pathways in patients with rheumatoid arthritis. Autoimmunity 44:235-242
66. Marrelli A, Cipriani P, Liakouli V, Carubbi F, Perricone C, Perricone R et al (2011) Angiogenesis in rheumatoid arthritis: a disease specific process or a common response to chronic inflammation? Autoimmun Rev 10:595-598
67. Nakken B, Munthe LA, Konttinen YT, Sandberg AK, Szekanecz Z, Alex P et al (2011) B-cells and their targeting in rheumatoid arthritis-current concepts and future perspectives. Autoimmun Rev 11:28-34
68. Ospelt C, Reedquist KA, Gay S, Tak PP (2011) Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun Rev 10:519-524
69. Perricone C, Ceccarelli F, Valesini G (2011) An overview on the genetic of rheumatoid arthritis: a never-ending story. Autoimmun Rev 10:599-608
70. Polido-Pereira J, Vieira-Sousa E, Fonseca JE (2011) Rheumatoid arthritis: what is refractory disease and how to manage it? Autoimmun Rev 10:707-713
71. Prete M, Racanelli V, Digiglio L, Vacca A, Dammacco F, Perosa F (2011) Extra-articular manifestations of rheumatoid arthritis: an update. Autoimmun Rev 11:123-131
72. Somers K, Geusens P, Elewaut D, De Keyser F, Rummens JL, Coenen M et al (2011) Novel autoantibody markers for early and seronegative rheumatoid arthritis. J Autoimmun 36:33-46
73. Tian J, Yong J, Dang H, Kaufman DL (2011) Oral GABA treatment downregulates inflammatory responses in a mouse model of rheumatoid arthritis. Autoimmunity 44:465-470
74. Behrens M, Smart M, Luckey D, Luthra H, Taneja V (2011) To B or not to B: role of B cells in pathogenesis of arthritis in HLA transgenic mice. J Autoimmun 37:95-103
75. Hoffmann MH, Skriner K, Herman S, Baumann C, Steiner CW, Ospelt C et al (2011) Nucleic acid-stimulated antigen-presenting cells trigger T cells to induce disease in a rat transfer model of inflammatory arthritis. J Autoimmun 36:288-300
76. Danieli MG, Pettinari L, Moretti R, Logullo F, Gabrielli A (2011) Subcutaneous immunoglobulin in polymyositis and dermatomyositis: a novel application. Autoimmun Rev 10:144-149
77. Marie I, Guillevin L, Menard JF, Hatron PY, Cherin P, Amoura Z et al (2012) Hematological malignancy associated with polymyositis and dermatomyositis. Autoimmun Rev 11:615-620
78. Marie I, Mouthon L (2011) Therapy of polymyositis and dermatomyositis. Autoimmun Rev 11:6-13
79. Selmi C, Meroni PL, Gershwin ME (2012) Primary biliary cirrhosis and Sjogren's syndrome: autoimmune epithelitis. J Autoimmun 39(1-2):34-42
80. Zhang W, Ono Y, Miyamura Y, Bowlus CL, Gershwin ME, Maverakis E (2011) Tcell clonal expansions detected in patients with primary biliary cirrhosis express CX3CR1. J Autoimmun 37:71-78
81. Naiyanetr P, Butler JD, Meng L, Pfeiff J, Kenny TP, Guggenheim KG et al (2011) Electrophile-modified lipoic derivatives of PDCE2 elicits anti-mitochondrial antibody reactivity. J Autoimmun 37:209-216
82. Hernandez-Molina G, Leal-Alegre G, Michel-Peregrina M (2011) The meaning of anti-Ro and anti-La antibodies in primary Sjogren's syndrome. Autoimmun Rev 10:123-125
83. Nginamau ES, Maehle BO, Jonsson R (2011) An experimental protocol for the fractionation and 2DE separation of HeLa and A-253 cell lysates suitable for the identification of the individual antigenic proteome in Sjogren's syndrome. Autoimmunity 44:652-663
84. Baldini C, Talarico R, Tzioufas AG, Bombardieri S (2011) Classification criteria for Sjogren's syndrome: a critical review. J Autoimmun. doi:10.1016/j.jaut.2011.12.006
85. Kapsogeorgou EK, Gourzi VC, Manoussakis MN, Moutsopoulos HM, Tzioufas AG (2011) Cellular microRNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression. J Autoimmun 37:129-135
86. Aguirre-Cruz L, Flores-Rivera J, De La Cruz-Aguilera DL, Rangel-Lopez E, Corona T (2011) Multiple sclerosis in Caucasians and Latino Americans. Autoimmunity 44:571-575
87. Aharoni R, Vainshtein A, Stock A, Eilam R, From R, Shinder V et al (2011) Distinct pathological patterns in relapsing-remitting and chronic models of experimental autoimmune enchephalomyelitis and the neuroprotective effect of glatiramer acetate. J Autoimmun 37:228-241
88. Baugh M, Black D, Westwood P, Kinghorn E, McGregor K, Bruin J et al (2011) Therapeutic dosing of an orally active, selective cathepsin S inhibitor suppresses disease in models of autoimmunity. J Autoimmun 36:201-209
89. Baughman EJ, Mendoza JP, Ortega SB, Ayers CL, Greenberg BM, Frohman EM et al (2011) Neuroantigen-specific CD8+ regulatory T-cell function is deficient during acute exacerbation of multiple sclerosis. J Autoimmun 36:115-124
90. Berzins SP, Smyth MJ, Baxter AG (2011) Presumed guilty: natural killer T cell defects and human disease. Nat Rev Immunol 11:131-142
91. Bjorkhem I, Diczfalusy U, Olsson T, Russell DW, McDonald JG, Wang Y et al (2011) Detecting oxysterols in the human circulation. Nat Immunol 12:577, author reply 8
92. Bjorkhem I, Lovgren-Sandblom A, Piehl F, Khademi M, Pettersson H, Leoni V et al (2011) High levels of 15-oxygenated steroids in circulation of patients with multiple sclerosis: fact or fiction? J Lipid Res 52:170-174
93. Borchers AT, Leibushor N, Cheema GS, Naguwa SM, Gershwin ME (2011) Immune-mediated adverse effects of biologicals used in the treatment of rheumatic diseases. J Autoimmun 37:273-288
94. Caielli S, Sorini C, Falcone M (2011) The dangerous liaison between iNKT cells and dendritic cells: does it prevent or promote autoimmune diseases? Autoimmunity 44:11-22
95. Chen Z, Freedman MS (2011) gammadelta T cells and multiple sclerosis: friends, foes, or both? Autoimmun Rev 10:364-367
96. Costenbader KH, Gay S, Riquelme ME, Iaccarino L, Doria A. Genes (2012) Epigenetic regulation and environmental factors: which is the most relevant in developing autoimmune diseases? Autoimmun Rev 11:604-609
97. Dreyfus DH (2011) Autoimmune disease: a role for new anti-viral therapies? Autoimmun Rev 11:88-97
98. Gobel K, Pankratz S, Schneider-Hohendorf T, Bittner S, Schuhmann MK, Langer HF et al (2011) Blockade of the kinin receptor B1 protects from autoimmune CNS disease by reducing leukocyte trafficking. J Autoimmun 36:106-114
99. Haas J, Bekeredjian-Ding I, Milkova M, Balint B, Schwarz A, Korporal M et al (2011) B cells undergo unique compartmentalized redistribution in multiple sclerosis. J Autoimmun 37:289-299
100. Haylock-Jacobs S, Comerford I, Bunting M, Kara E, Townley S, Klingler-Hoffmann M et al (2011) PI3Kdelta drives the pathogenesis of experimental autoimmune encephalomyelitis by inhibiting effector T cell apoptosis and promoting Th17 differentiation. J Autoimmun 36:278-287
101. Haylock-Jacobs S, Keough MB, Lau L, Yong VW (2011) Chondroitin sulphate proteoglycans: extracellular matrix proteins that regulate immunity of the central nervous system. Autoimmun Rev 10:766-772
102. Jiang W, Chai NR, Maric D, Bielekova B (2011) Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis. J Immunol 187:781-790
103. Lelu K, Laffont S, Delpy L, Paulet PE, Perinat T, Tschanz SA et al (2011) Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol 187:2386-2393
104. Luckey D, Bastakoty D, Mangalam AK (2011) Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice. J Autoimmun 37:122-128
105. Papenfuss TL, Powell ND, McClain MA, Bedarf A, Singh A, Gienapp IE et al (2011) Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 186:3346-3355
106. Piconese S, Costanza M, Tripodo C, Sangaletti S, Musio S, Pittoni P et al (2011) The matricellular protein SPARC supports follicular dendritic cell networking toward Th17 responses. J Autoimmun 37:300-310
107. Richards MH, Getts MT, Podojil JR, Jin YH, Kim BS, Miller SD (2011) Virus expanded regulatory T cells control disease severity in the Theiler's virus mouse model of MS. J Autoimmun 36:142-154
108. Selin LK, Wlodarczyk MF, Kraft AR, Nie S, Kenney LL, Puzone R et al (2011) Heterologous immunity: immunopathology, autoimmunity and protection during viral infections. Autoimmunity 44:328-347
109. Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O (2011) The increasing incidence and prevalence of female multiple sclerosis - a critical analysis of potential environmental factors. Autoimmun Rev 10:495-502
110. Wootla B, Lacroix-Desmazes S, Warrington AE, Bieber AJ, Kaveri SV, Rodriguez M (2011) Autoantibodies with enzymatic properties in human autoimmune diseases. J Autoimmun 37:144-150
111. Wu GF, Shindler KS, Allenspach EJ, Stephen TL, Thomas HL, Mikesell RJ et al (2011) Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. J Autoimmun 36:56-64
112. Yeh WI, McWilliams IL, Harrington LE (2011) Autoreactive Tbet-positive CD4 T cells develop independent of classic Th1 cytokine signaling during experimental autoimmune encephalomyelitis. J Immunol 187:4998-5006
113. Zhang Q, Lin CY, Dong Q, Wang J, Wang W (2011) Relationship between HLA-DRB1 polymorphism and susceptibility or resistance to multiple sclerosis in Caucasians: a meta-analysis of nonfamily-based studies. Autoimmun Rev 10:474-481
114. Bresson D, Fousteri G, Manenkova Y, Croft M, von Herrath M (2011) Antigen-specific prevention of type 1 diabetes in NOD mice is ameliorated by OX40 agonist treatment. J Autoimmun 37:342-351
115. Li CR, Deiro MF, Godebu E, Bradley LM (2011) IL-7 uniquely maintains FoxP3(+) adaptive Treg cells that reverse diabetes in NOD mice via integrin-beta7-dependent localization. J Autoimmun 37:217-227
116. Hasham A, Tomer Y (2011) The recent rise in the frequency of type 1 diabetes: who pulled the trigger? J Autoimmun 37:1-2
117. Kaminitz A, Yolcu ES, Stein J, Yaniv I, Shirwan H, Askenasy N (2011) Killer Treg restore immune homeostasis and suppress autoimmune diabetes in prediabetic NOD mice. J Autoimmun 37:39-47
118. Roy E, Leduc M, Guegan S, Rachdi L, Kluger N, Scharfmann R et al (2011) Specific maternal microchimeric T cells targeting fetal antigens in beta cells predispose to auto-immune diabetes in the child. J Autoimmun 36:253-262
119. Ziegler AG, Pflueger M, Winkler C, Achenbach P, Akolkar B, Krischer JP et al (2011) Accelerated progression from islet autoimmunity to diabetes is causing the escalating incidence of type 1 diabetes in young children. J Autoimmun 37:3-7
120. Kornete M, Piccirillo CA (2011) Critical co-stimulatory pathways in the stability of Foxp3+ Treg cell homeostasis in type I diabetes. Autoimmun Rev 11:104-111
121. Espino-Paisan L, De La Calle H, Fernandez-Arquero M, Figueredo MA, De La Concha EG, Urcelay E et al (2011) Study of polymorphisms in 4q27, 10p15, and 22q13 regions in autoantibodies stratified type 1 diabetes patients. Autoimmunity 44:624-630
122. Andersson C, Larsson K, Vaziri-Sani F, Lynch K, Carlsson A, Cedervall E et al (2011) The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes. Autoimmunity 44:394-405
123. Brorsson C, Vaziri-Sani F, Bergholdt R, Eising S, Nilsson A, Svensson J et al (2011) Correlations between islet autoantibody specificity and the SLC30A8 genotype with HLA-DQB1 and metabolic control in new onset type 1 diabetes. Autoimmunity 44:107-114
124. Morris MA, McDuffie M, Nadler JL, Ley K (2011) Prevention, but not cure, of autoimmune diabetes in a NOD.scid transfer model by FTY720 despite effective modulation of blood T cells. Autoimmunity 44:115-128
125. Kruger AJ, Yang C, Lipson KL, Pino SC, Leif JH, Hogan CM et al (2011) Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats. Autoimmunity 44:137-148
126. Hansson I, Lynch KF, Hallmans G, Lernmark A, Rolandsson O (2011) High-titer GAD65 autoantibodies detected in adult diabetes patients using a high efficiency expression vector and cold GAD65 displacement. Autoimmunity 44:129-136
127. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11:98-107
128. Kim DH, Lee JC, Kim S, Oh SH, Lee MK, Kim KW et al (2011) Inhibition of autoimmune diabetes by TLR2 tolerance. J Immunol 187:5211-5220
129. Tada A, Shimada A, Yamada T, Oikawa Y, Yamada Y, Okubo Y et al (2011) A mimic of viral double-stranded RNA triggers fulminant type 1 diabetes-like syndrome in regulatory T cell-deficient autoimmune diabetic mouse. J Immunol 187:4947-4953
130. Bettini M, Szymczak-Workman AL, Forbes K, Castellaw AH, Selby M, Pan X et al (2011) Cutting edge: accelerated autoimmune diabetes in the absence of LAG-3. J Immunol 187:3493-3498
131. Lee IF, van den Elzen P, Tan R, Priatel JJ (2011) NKT cells are required for complete Freund's adjuvant-mediated protection from autoimmune diabetes. J Immunol 187:2898-2904
132. Van Belle TL, Esplugues E, Liao J, Juntti T, Flavell RA, von Herrath MG (2011) Development of autoimmune diabetes in the absence of detectable IL-17A in a CD8-driven virally induced model. J Immunol 187:2915-2922
133. Herold KC, Pescovitz MD, McGee P, Krause-Steinrauf H, Spain LM, Bourcier K et al (2011) Increased T cell proliferative responses to islet antigens identify clinical responders to anti-CD20 monoclonal antibody (rituximab) therapy in type 1 diabetes. J Immunol 187:1998-2005
134. Rainbow DB, Moule C, Fraser HI, Clark J, Howlett SK, Burren O et al (2011) Evidence that Cd101 is an autoimmune diabetes gene in nonobese diabetic mice. J Immunol 187:325-336
135. Ghaemi Oskouie F, Shameli A, Yang A, Desrosiers MD, Mucsi AD, Blackburn MR et al (2011) High levels of adenosine deaminase on dendritic cells promote autoreactive T cell activation and diabetes in nonobese diabetic mice. J Immunol 186:6798-6806
136. Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC et al (2011) Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol 186:6056-6063
137. Ramanathan S, Dubois S, Chen XL, Leblanc C, Ohashi PS, Ilangumaran S (2011) Exposure to IL-15 and IL-21 enables autoreactive CD8 T cells to respond to weak antigens and cause disease in a mouse model of autoimmune diabetes. J Immunol 186:5131-5141
138. McClymont SA, Putnam AL, Lee MR, Esensten JH, Liu W, Hulme MA et al (2011) Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 186:3918-3926
139. Chen YG, Scheuplein F, Driver JP, Hewes AA, Reifsnyder PC, Leiter EH et al (2011) Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice. J Immunol 186:4278-4284
140. Codina-Busqueta E, Scholz E, Munoz-Torres PM, Roura-Mir C, Costa M, Xufre C et al (2011) TCR bias of in vivo expanded T cells in pancreatic islets and spleen at the onset in human type 1 diabetes. J Immunol 186:3787-3797
141. Goudy KS, Johnson MC, Garland A, Li C, Samulski RJ, Wang B et al (2011) Inducible adeno-associated virus-mediated IL-2 gene therapy prevents autoimmune diabetes. J Immunol 186:3779-3786
142. Lau K, Benitez P, Ardissone A, Wilson TD, Collins EL, Lorca G et al (2011) Inhibition of type 1 diabetes correlated to a Lactobacillus johnsonii N6.2-mediated Th17 bias. J Immunol 186:3538-3546
143. Kapoor S (2011) Comment on "Therapeutic targeting of Syk in autoimmune diabetes". J Immunol 186:1885, author reply 6-5
144. Hillebrands JL, Rozing J, Visser JT (2011) Comment on "Type 1 diabetes in BioBreeding rats is critically linked to an imbalance between Th17 and regulatory T cells and an altered TCR repertoire". J Immunol 186:1297-1298, author reply 8-9
145. Hoyne GF, Flening E, Yabas M, Teh C, Altin JA, Randall K et al (2011) Visualizing the role of Cbl-b in control of islet-reactive CD4 T cells and susceptibility to type 1 diabetes. J Immunol 186:2024-2032
146. Jagannathan-Bogdan M, McDonnell ME, Shin H, Rehman Q, Hasturk H, Apovian CM et al (2011) Elevated proinflammatory cytokine production by a skewed T cell compartment requires monocytes and promotes inflammation in type 2 diabetes. J Immunol 186:1162-1172
147. Unger WW, Velthuis J, Abreu JR, Laban S, Quinten E, Kester MG et al (2011) Discovery of low-affinity preproinsulin epitopes and detection of autoreactive CD8 T-cells using combinatorial MHC multimers. J Autoimmun 37:151-159
148. Ge X, James EA, Reijonen H, Kwok WW (2011) Differences in self-peptide binding between T1D-related susceptible and protective DR4 subtypes. J Autoimmun 36:155-160
149. Aricha R, Feferman T, Scott HS, Souroujon MC, Berrih-Aknin S, Fuchs S (2011) The susceptibility of Aire(-/-)mice to experimental myasthenia gravis involves alterations in regulatory T cells. J Autoimmun 36:16-24
150. Aricha R, Mizrachi K, Fuchs S, Souroujon MC (2011) Blocking of IL-6 suppresses experimental autoimmune myasthenia gravis. J Autoimmun 36:135-141
151. Tuzun E, Huda R, Christadoss P (2011) Complement and cytokine based therapeutic strategies in myasthenia gravis. J Autoimmun 37:136-143
152. Levy D, Kuo AJ, Chang Y, Schaefer U, Kitson C, Cheung P et al (2011) Lysine methylation of the NF-kappaB subunit RelA by SETD6 couples activity of the histone methyltransferase GLP at chromatin to tonic repression of NF-kappaB signaling. Nat Immunol 12:29-36
153. Mandal M, Powers SE, Maienschein-Cline M, Bartom ET, Hamel KM, Kee BL et al (2011) Epigenetic repression of the Igk locus by STAT5-mediated recruitment of the histone methyltransferase Ezh2. Nat Immunol 12:1212-1220
154. Navarro MN, Goebel J, Feijoo-Carnero C, Morrice N, Cantrell DA (2011) Phosphoproteomic analysis reveals an intrinsic pathway for the regulation of histone deacetylase 7 that controls the function of cytotoxic T lymphocytes. Nat Immunol 12:352-361
155. Zust R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, Ziebuhr J et al (2011) Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12:137-143
156. Kim S, Lee S, Shin J, Kim Y, Evnouchidou I, Kim D et al (2011) Human cytomegalovirus microRNA miR-US4-1 inhibits CD8(+) T cell responses by targeting the aminopeptidase ERAP1. Nat Immunol 12:984-991
157. Ma F, Xu S, Liu X, Zhang Q, Xu X, Liu M et al (2011) The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon-gamma. Nat Immunol 12:861-869
158. Rossi RL, Rossetti G, Wenandy L, Curti S, Ripamonti A, Bonnal RJ et al (2011) Distinct microRNA signatures in human lymphocyte subsets and enforcement of the naive state in CD4+ T cells by the microRNA miR-125b. Nat Immunol 12:796-803
159. Racanelli V, Prete M, Musaraj G, Dammacco F, Perosa F (2011) Autoantibodies to intracellular antigens: generation and pathogenetic role. Autoimmun Rev 10:503-508
160. Sagi L, Baum S, Agmon-Levin N, Sherer Y, Katz BS, Barzilai O et al (2011) Autoimmune bullous diseases the spectrum of infectious agent antibodies and review of the literature. Autoimmun Rev 10:527-535
161. Mortellaro A, Ricciardi-Castagnoli P (2011) From vaccine practice to vaccine science: the contribution of human immunology to the prevention of infectious disease. Immunol Cell Biol 89:332-339
162. Deshmukh US, Sim DL, Dai C, Kannapell CJ, Gaskin F, Rajagopalan G et al (2011) HLA-DR3 restricted T cell epitope mimicry in induction of autoimmune response to lupus-associated antigen SmD. J Autoimmun 37:254-262
163. Hintermann E, Holdener M, Bayer M, Loges S, Pfeilschifter JM, Granier C et al (2011) Epitope spreading of the anti-CYP2D6 antibody response in patients with autoimmune hepatitis and in the CYP2D6 mouse model. J Autoimmun 37:242-253
164. Wang YH, Yan Y, Rice JS, Volpe BT, Diamond B (2011) Enforced expression of the apoptosis inhibitor Bcl-2 ablates tolerance induction in DNA-reactive B cells through a novel mechanism. J Autoimmun 37:18-27
165. Borbulevych OY, Piepenbrink KH, Baker BM (2011) Conformational melding permits a conserved binding geometry in TCR recognition of foreign and self molecular mimics. J Immunol 186:2950-2958
166. Pellicci DG, Clarke AJ, Patel O, Mallevaey T, Beddoe T, Le Nours J et al (2011) Recognition of beta-linked self glycolipids mediated by natural killer T cell antigen receptors. Nat Immunol 12:827-833
167. Mills KH (2011) TLR-dependent T cell activation in autoimmunity. Nat Rev Immunol 11:807-822
168. Meroni PL (2011) Autoimmune or auto-inflammatory syndrome induced by adjuvants (ASIA): old truths and a new syndrome? J Autoimmun 36:1-3
169. Shoenfeld Y, Agmon-Levin N (2011) 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 36:4-8
170. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593-595
171. Cacciapaglia F, Navarini L, Menna P, Salvatorelli E, Minotti G, Afeltra A (2011) Cardiovascular safety of anti-TNF-alpha therapies: facts and unsettled issues. Autoimmun Rev 10:631-635
172. Miserocchi E, Pontikaki I, Modorati G, Gattinara M, Meroni PL, Gerloni V (2011) Anti-CD 20 monoclonal antibody (rituximab) treatment for inflammatory ocular diseases. Autoimmun Rev 11:35-39
173. Pons-Estel GJ, Serrano R, Plasin MA, Espinosa G, Cervera R (2011) Epidemiology and management of refractory lupus nephritis. Autoimmun Rev 10:655-663
174. Rosenblum H, Amital H (2011) Anti-TNF therapy: safety aspects of taking the risk. Autoimmun Rev 10:563-568
175. Warter L, Lee CY, Thiagarajan R, Grandadam M, Lebecque S, Lin RT et al (2011) Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 186:3258-3264
176. Bonaguri C, Melegari A, Ballabio A, Parmeggiani M, Russo A, Battistelli L et al (2011) Italian multicentre study for application of a diagnostic algorithm in autoantibody testing for autoimmune rheumatic disease: conclusive results. Autoimmun Rev 11:1-5
177. Hu N, Westra J, Kallenberg CG (2011) Dysregulated neutrophil-endothelial interaction in antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides: implications for pathogenesis and disease intervention. Autoimmun Rev 10:536-543
178. Outschoorn IM, Talor MV, Hoffman WH, Rowley MJ, Mackay IR, Rose NR et al (2011) Autoantibody heritability in thyroiditis: IgG subclass contributions. Autoimmunity 44:195-200
179. Xu Z, Vallurupalli A, Fuhrman C, Ostrov D, Morel L (2011) A New Zealand Black-derived locus suppresses chronic graft-versus-host disease and autoantibody production through nonlymphoid bone marrow-derived cells. J Immunol 186:4130-4139
180. Bahcheli D, Hay V, Nadeau JL, Piccirillo CA (2011) Transfer of cell membrane components via trogocytosis occurs in CD4+ Foxp3+ CD25+ regulatory T-cell contact-dependent suppression. Autoimmunity 44:607-615
181. Dagur PK, Biancotto A, Wei L, Sen HN, Yao M, Strober W et al (2011) MCAM-expressing CD4(+) T cells in peripheral blood secrete IL-17A and are significantly elevated in inflammatory autoimmune diseases. J Autoimmun 37:319-327
182. de Lalla C, Rinaldi A, Montagna D, Azzimonti L, Bernardo ME, Sangalli LM et al (2011) Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state. J Immunol 186:4490-4499
183. Dromey JA, Lee BH, Yu H, Young HE, Thearle DJ, Jensen KP et al (2011) Generation and expansion of regulatory human CD4(+) T-cell clones specific for pancreatic islet autoantigens. J Autoimmun 36:47-55
184. Housley WJ, Adams CO, Vang AG, Brocke S, Nichols FC, LaCombe M et al (2011) Peroxisome proliferator-activated receptor gamma is required for CD4+ T cell-mediated lymphopeniaassociated autoimmunity. J Immunol 187:4161-4169
185. Kaminski S, Hermann-Kleiter N, Meisel M, Thuille N, Cronin S, Hara H et al (2011) Coronin 1A is an essential regulator of the TGFbeta receptor/SMAD3 signaling pathway in Th17 CD4(+) T cells. J Autoimmun 37:198-208
186. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E et al (2012) Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev 11:670-677
187. Koh AE, Njoroge SW, Feliu M, Cook A, Selig MK, Latchman YE et al (2011) The SLAM family member CD48 (Slamf2) protects lupus-prone mice from autoimmune nephritis. J Autoimmun 37:48-57
188. Lai W, Yu M, Huang MN, Okoye F, Keegan AD, Farber DL (2011) Transcriptional control of rapid recall by memory CD4 T cells. J Immunol 187:133-140
189. Lalor SJ, Dungan LS, Sutton CE, Basdeo SA, Fletcher JM, Mills KH (2011) Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol 186:5738-5748
190. Long SA, Buckner JH (2011) CD4 + FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. J Immunol 187:2061-2066
191. Motomura Y, Kitamura H, Hijikata A, Matsunaga Y, Matsumoto K, Inoue H et al (2011) The transcription factor E4BP4 regulates the production of IL-10 and IL-13 in CD4+ T cells. Nat Immunol 12:450-459
192. Oh HM, Yu CR, Lee Y, Chan CC, Maminishkis A, Egwuagu CE (2011) Autoreactive memory CD4+ T lymphocytes that mediate chronic uveitis reside in the bone marrow through STAT3-dependent mechanisms. J Immunol 187:3338-3346
193. Pepper M, Jenkins MK (2011) Origins of CD4(+) effector and central memory T cells. Nat Immunol 12:467-471
194. Shameli A, Clemente-Casares X, Wang J, Santamaria P (2011) Development of memory-like autoregulatory CD8+ T cells is CD4+ T cell dependent. J Immunol 187:2859-2866
195. Sun J, Dodd H, Moser EK, Sharma R, Braciale TJ (2011) CD4+ T cell help and innate-derived IL-27 induce Blimp-1-dependent IL-10 production by antiviral CTLs. Nat Immunol 12:327-334
196. Tosiek MJ, Gruber AD, Bader SR, Mauel S, Hoymann HG, Prettin S et al (2011) CD4 + CD25 + Foxp3+ regulatory T cells are dispensable for controlling CD8+ T cell-mediated lung inflammation. J Immunol 186:6106-6118
197. Tucker CF, Nebane-Ambe DL, Chhabra A, Parnell SA, Zhao Y, Alard P et al (2011) Decreased frequencies of CD4+ CD25+ Foxp3+ cells and the potent CD103+ subset in peripheral lymph nodes correlate with autoimmune disease predisposition in some strains of mice. Autoimmunity 44:453-464
198. Zhou X, Kong N, Zou H, Brand D, Li X, Liu Z et al (2011) Therapeutic potential of TGF-beta-induced CD4(+) Foxp3(+) regulatory T cells in autoimmune diseases. Autoimmunity 44:43-50
199. Maddur MS, Kaveri SV, Bayry J (2011) Comparison of different IVIg preparations on IL-17 production by human Th17 cells. Autoimmun Rev 10:809-810
200. Wang YL, Chou FC, Chen SJ, Lin SH, Chang DM, Sytwu HK (2011) Targeting pre-ligand assembly domain of TNFR1 ameliorates autoimmune diseases - an unrevealed role in downregulation of Th17 cells. J Autoimmun 37:160-170
201. Carter NA, Vasconcellos R, Rosser EC, Tulone C, Munoz-Suano A, Kamanaka M et al (2011) Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. J Immunol 186:5569-5579
202. Katzman SD, Gallo E, Hoyer KK, Abbas AK (2011) Differential requirements for Th1 and Th17 responses to a systemic selfantigen. J Immunol 186:4668-4673
203. Pollinger B, Junt T, Metzler B, Walker UA, Tyndall A, Allard C et al (2011) Th17 cells, not IL-17+ gammadelta T cells, drive arthritic bone destruction in mice and humans. J Immunol 186:2602-2612
204. Stoehr AD, Schoen CT, Mertes MM, Eiglmeier S, Holecska V, Lorenz AK et al (2011) TLR9 in peritoneal B-1b cells is essential for production of protective self-reactive IgM to control Th17 cells and severe autoimmunity. J Immunol 187:2953-2965
205. Krausgruber T, Blazek K, Smallie T, Alzabin S, Lockstone H, Sahgal N et al (2011) IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 12:231-238
206. Filaci G, Fenoglio D, Indiveri F (2011) CD8(+) T regulatory/suppressor cells and their relationships with autoreactivity and autoimmunity. Autoimmunity 44:51-57
207. Hussain S, Kirwin SJ, Stohlman SA (2011) Increased T regulatory cells lead to development of Th2 immune response in male SJL mice. Autoimmunity 44:219-228
208. Chen M, Felix K, Wang J (2011) Immune regulation through mitochondrion-dependent dendritic cell death induced by T regulatory cells. J Immunol 187:5684-5692
209. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M (2011) Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995. J Immunol 186:3808-3821
210. Hegde S, Lockridge JL, Becker YA, Ma S, Kenney SC, Gumperz JE (2011) Human NKT cells direct the differentiation of myeloid APCs that regulate T cell responses via expression of programmed cell death ligands. J Autoimmun 37:28-38
211. Sharma R, Sung SS, Ju CY, Deshmukh US, Fu SM, Ju ST (2011) Regulatory T-Cell (Treg) hybridoma as a novel tool to study Foxp3 regulation and Treg fate. J Autoimmun 37:113-121
212. Farrar MA, Harris LM (2011) Turning transcription on or off with STAT5: when more is less. Nat Immunol 12:1139-1140
213. Cakir M, Levendoglu F, Kiyici A, Coskun Y (2011) Serum CXCL10 levels and neuromuscular manifestations in patients with autoimmune thyroid diseases. Autoimmunity 44:496-503
214. Loh C, Pau E, Lajoie G, Li TT, Baglaenko Y, Cheung YH et al (2011) Epistatic suppression of fatal autoimmunity in New Zealand black bicongenic mice. J Immunol 186:5845-5853
215. Mittag D, Proietto AI, Loudovaris T, Mannering SI, Vremec D, Shortman K et al (2011) Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 186:6207-6217
216. Yang XP, Ghoreschi K, Steward-Tharp SM, Rodriguez-Canales J, Zhu J, Grainger JR et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12:247-254
217. Sharma R, Fu SM, Ju ST (2011) IL-2: a two-faced master regulator of autoimmunity. J Autoimmun 36:91-97
218. Fletcher CA, Groom JR, Woehl B, Leung H, Mackay C, Mackay F (2011) Development of autoimmune nephritis in genetically asplenic and splenectomized BAFF transgenic mice. J Autoimmun 36:125-134
219. Fousteri G, Dave A, Morin B, Omid S, Croft M, von Herrath MG (2011) Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis. J Autoimmun 36:210-220